Editorial: New therapeutic agents for castration-refractory prostate cancer

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Patten, David ^a   Sartor, Oliver ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ATRASENTAN; BEVACIZUMAB; BOLDENONE; CABAZITAXEL; DASATINIB; DOCETAXEL; LENALIDOMIDE; MDV 3100; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OGX 011; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RADIUM 223; SATRAPLATIN; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; XRP 6258; ANDROSTANE DERIVATIVE; DRUG DERIVATIVE; ENDOTHELIN; PHENYLTHIOHYDANTOIN; PROTEIN KINASE INHIBITOR; SIPULEUCEL-T; THALIDOMIDE; TISSUE EXTRACT;

ANDROGEN DEPRIVATION THERAPY; BONE PAIN; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION REFRACTORY PROSTATE CANCER; CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HUMAN; MONOTHERAPY; PROSTATE CANCER; RECURRENT CANCER; TESTOSTERONE BLOOD LEVEL; DRUG ANTAGONISM; MALE; ORCHIECTOMY; PHYSIOLOGY; PROSTATE TUMOR;

ANDROSTENOLS; ENDOTHELINS; HUMANS; MALE; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; THALIDOMIDE; TISSUE EXTRACTS;

EID: 70449427422     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.013     Document Type: Editorial

References (15)

1. Tannock I, Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512
2. Stanbrough M, Bubley G, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825
3. Danila D, Rathcompf D, Morris M, et al. Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol 2008; 26(suppl):254s (Abstract 5019).
4. Scher H, Beer T, Higano C, et al. Phase I/II of MDV3100 in patients with progressive castration-resistant prostate cancer (CRPC). J Clin Oncol 2008; 26(suppl):251s (Abstract 5006).
5. Small E, Schellhammer P, Higano C, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2996; 24:3089-3094
6. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients with advanced solid tumors: Preliminary results. J Clin Oncol 2008; 26(suppl):177s (Abstract 3599).
7. Di Lorenzo G, Figg W, Fossa S, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 study. Eur Urol 2008; 54:1089-1094
8. Yu E, Wilding G, Posadas E, et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. J Clin Oncol 2008; 26(suppl):288s (Abstract 5156).
9. Periman P, Sonpavde D, Bernold D, et al. Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel based chemotherapy. J Clin Oncol 2008; 26(suppl):288s (Abstract 5157).
10. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113:2478-2487
11. Dawson N, Phung T, Morris M, et al. Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a phase II trial. Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 7.
12. Nilsson S, Franzen L, Parker C, et al. Bone targeted radium-223 for in symptomatic hormone-refractory prostate cancer: a randomized multicentre placebocontrolled Phase II study. Lancet Oncol 2007; 8:587-594
13. Press release (Oncogenex December 3, 2008). OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study. Availablet at: http://ir.oncogenex.com/releasedetail. cfm?ReleaseID=351924. Accessed: August 7, 2009.
14. Dahut W, Gulley J, Arlen P, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2932-2939
15. Ning Y, Arlen P, Gulley J, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 2008; 26(suppl):250s (Abstract 5000).